EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of Pf Ark1 and Hemozoin Formation

Kathryn J Wicht iD, John G Woodland iD, Larnelle F Garnie, Henrico Langeveld, Dale Taylor, Luiz C Godoy, Charisse Flerida A Pasaje, Mariana Laureano de Souza iD, Jair L Siqueira-Neto, Sonja Ghidelli-Disse, Maria Jose Lafuente-Monasterio, Francisco-Javier Gamo iD und 18 weitere

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Kathryn J Wicht und 29 weiteren Autor:innen. Beteiligte Einrichtung: Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Checkpoint Kinase 1, Hemeproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Royal Society, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high burden of malaria and growing resistance to frontline antimalarials demand new drug target combinations with reduced propensities for conferring parasite resistance. An attractive approach for circumventing antimalarial drug resistance is target repurposing, in which known drugs that act through protein targets of human origin that are also active against the human malaria parasite Plasmodium falciparum are exploited to identify novel antimalarial drug targets. Here, we show that the human checkpoint kinase 1 (Chk1) inhibitor CHIR-124 is active in vitro against both drug-sensitive and drug-resistant asexual blood stage parasites and competitively binds to several Plasmodium kinases. The compound also shows moderate activity against both the liver and gametocyte forms of the parasite. Further target investigation of CHIR-124 via conditional knockdown experiments confirmed that P. falciparum Aurora-related kinase 1 (PfArk1) is implicated in its parasiticidal activity. Notably, CHIR-124 also inhibits β-hematin (synthetic hemozoin) formation and causes a dose-dependent increase in free heme that correlates with inhibition of parasite growth. These findings suggest that polypharmacology is involved in the activity of CHIR-124 against P. falciparum via the dual inhibition of Plasmodium PfArk1 and hemozoin formation, both essential for parasite proliferation. This is further supported by in vitro drug combination experiments, morphological studies, and resistance generation attempts. This study validates the feasibility of dual Plasmodium kinase/hemozoin formation inhibitors active against resistant strains with decreased resistance risks in the fight against malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsCheckpoint Kinase 1HemeproteinsProtein Kinase InhibitorsProtozoan ProteinsHumansMalaria, Falciparum

Substanzen

AntimalarialshemozoinCheckpoint Kinase 1HemeproteinsProtein Kinase InhibitorsCHEK1 protein, humanProtozoan Proteins

Autor:innen und Institutionen

  • Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.
  • South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, South A…
  • Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
  • Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
  • Department of Biochemistry, Stellenbosch University, Stellenbosch 7600, South Africa.
  • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.

ORCID-Profile: Kathryn J Wicht, John G Woodland, Mariana Laureano de Souza, Francisco-Javier Gamo, Sergio Wittlin, Jacquin C Niles, Lyn-Marié Birkholtz, Lauren B Coulson, Kelly Chibale

Förderung

  • NIAID NIH HHS
  • Royal Society
  • National Institute of Allergy and Infectious Diseases
  • African Academy of Sciences
  • Bill and Melinda Gates Foundation
  • Medicines for Malaria Venture
  • National Research Foundation
  • South African Medical Research Council

Zitieren

APA

Wicht, K. J., Woodland, J. G., Garnie, L. F., Langeveld, H., Taylor, D., Godoy, L. C., Pasaje, C. F. A., Laureano de Souza, M., Siqueira-Neto, J. L., Ghidelli-Disse, S., Lafuente-Monasterio, M. J., Gamo, F. J., Coertzen, D., Reader, J., van der Watt, M., Bridgford, J. L., Girling, G., Coyle, R., Scheurer, C., …, & Chibale, K. (2026). The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of Pf Ark1 and Hemozoin Formation. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00264

Vancouver

Wicht KJ, Woodland JG, Garnie LF, Langeveld H, Taylor D, Godoy LC, et al. The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of Pf Ark1 and Hemozoin Formation. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00264

BibTeX
@article{Wicht2026,
  author = {Wicht, Kathryn J and Woodland, John G and Garnie, Larnelle F and Langeveld, Henrico and Taylor, Dale and Godoy, Luiz C and Pasaje, Charisse Flerida A and Laureano de Souza, Mariana and Siqueira-Neto, Jair L and Ghidelli-Disse, Sonja and Lafuente-Monasterio, Maria Jose and Gamo, Francisco-Javier and Coertzen, Dina and Reader, Janette and van der Watt, Mariëtte and Bridgford, Jessica L and Girling, Gareth and Coyle, Rachael and Scheurer, Christian and Wittlin, Sergio and Alder, Arne and Gilberger, Tim-Wolf and Lee, Marcus C S and Voss, Till S and Winzeler, Elizabeth A and Fidock, David A and Niles, Jacquin C and Birkholtz, Lyn-Marié and Coulson, Lauren B and Chibale, Kelly},
  title = {The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of Pf Ark1 and Hemozoin Formation},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00264}
}
Kostenlos starten →